Neurogenesis, Inc.
Neurogenesis, Inc.
Aktie · US64124F3010 (OTC)
Übersicht
Kein Kurs
Schlusskurs OTC 30.10.2025: 0,0001 USD
30.10.2025 20:00
Aktuelle Kurse von Neurogenesis, Inc.
BörseTickerWährungLetzter UmsatzKursTagesveränderung
OTC: UTC
UTC
NEUN
USD
30.10.2025 20:00
0,0001 USD
0,00 USD
Firmenprofil zu Neurogenesis, Inc. Aktie
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
Erhalte tagesaktuelle Insights vom finAgent über Neurogenesis, Inc.

Unternehmensdaten

Name Neurogenesis, Inc.
Firma Neurogenesis, Inc.
Website https://www.neurogenesis.com
Heimatbörse OTC UTC
ISIN US64124F3010
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Tal Gilat
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter -
Adresse 1241 Butler Road, 77573 League City
IPO Datum 1998-06-08

Ticker Symbole

Name Symbol
Over The Counter NEUN
Weitere Aktien
Investoren, die Neurogenesis, Inc. halten, haben auch folgende Aktien im Depot:
CRANE CO 2048
CRANE CO 2048 Anleihe
Kyodo Printing Co., Ltd.
Kyodo Printing Co., Ltd. Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025